Sanguinete Marcela Moisés Maluf, Oliveira Paula Honório De, Martins-Filho Agrimaldo, Micheli Douglas Côbo, Tavares-Murta Beatriz Martins, Murta Eddie Fernando Candido, Nomelini Rosekeila Simões
a Research Institute of Oncology (IPON)/Discipline of Gynecology and Obstetrics , Federal University of Triângulo Mineiro , Uberaba , MG , Brazil.
b Discipline of Pharmacology , Federal University of Triângulo Mineiro , Uberaba , MG , Brazil.
Immunol Invest. 2017 Oct;46(7):677-688. doi: 10.1080/08820139.2017.1360342.
The aim of the study was to correlate serum levels of IL-2, IL-5, IL-6, IL-8, IL-10, and TNF-α with clinical, laboratory, and pathological prognostic factors in patients with primary ovarian malignancy. Patients treated at the Pelvic Mass Ambulatory of the Discipline of Gynecology and Obstetrics/Oncology Research Institute (IPON) of the UFTM with confirmed diagnosis of malignant ovarian neoplasia (n = 26) were evaluated. Serum collection was performed preoperatively for the determination of tumor markers. The cytokines IL-2, IL-5, IL-6, IL-8, IL-10, and TNF-α were assayed by enzyme-linked immunosorbent assay (ELISA). The prognostic factors were compared using the Mann-Whitney test, with significance level lower than 0.05. When evaluating IL6, it was observed that higher serum levels were associated with overall survival less than 60 months (p = 0.0382). In the evaluation of IL8, higher serum levels were associated with neutrophil-to-lymphocyte ratio (NLR) ≥ 4 and platelet-to-lymphocyte ratio (PLR) ≥ 200 (p = 0.0198 and p = 0.0072, respectively), altered values of serum CA125 (p = 0.0457), and stage IIIC (p = 0.0486). Therefore, increased levels of IL-6 and IL-8 are associated with factors of worse prognosis in ovarian cancer. Additional studies with a larger sample of patients are needed to confirm the role of cytokines as prognostic factors, in the definition of treatment, and in the development of future target therapies.
本研究的目的是将原发性卵巢恶性肿瘤患者血清中的白细胞介素-2（IL-2）、白细胞介素-5（IL-5）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、白细胞介素-10（IL-10）和肿瘤坏死因子-α（TNF-α）水平与临床、实验室及病理预后因素进行关联分析。对在乌法联邦大学妇产科/肿瘤研究所（IPON）盆腔肿块门诊接受治疗且确诊为恶性卵巢肿瘤的患者（n = 26）进行了评估。术前采集血清以测定肿瘤标志物。采用酶联免疫吸附测定法（ELISA）检测细胞因子IL-2、IL-5、IL-6、IL-8、IL-10和TNF-α。使用曼-惠特尼检验比较预后因素，显著性水平低于0.05。在评估IL6时，发现血清水平较高与总生存期少于60个月相关（p = 0.0382）。在评估IL8时，血清水平较高与中性粒细胞与淋巴细胞比值（NLR）≥4和血小板与淋巴细胞比值（PLR）≥200相关（分别为p = 0.0198和p = 0.0072），血清CA125值改变（p = 0.0457），以及IIIC期（p = 0.0486）。因此，IL-6和IL-8水平升高与卵巢癌预后较差的因素相关。需要对更多患者样本进行进一步研究，以证实细胞因子作为预后因素在治疗定义和未来靶向治疗开发中的作用。
